[ARDM] Aradigm Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.62 Change: -0.02 (-1.22%)
Ext. hours: Change: 0 (0%)

chart ARDM

Refresh chart

Strongest Trends Summary For ARDM

ARDM is in the long-term down -88% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the treatment and prevention of respiratory diseases by pulmonologists. The company?s lead development candidates include Pulmaquin (ARD-3150) and Lipoquin (ARD-3100), which completed Phase IIb clinical trials for the management of infections associated with the severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). Its products under development also comprise ARD-1100, a liposomal ciprofloxacin for the treatment of inhalation anthrax and other biodefense purposes; and ARD-1600, an inhaled nicotine product for smoking cessation. The company has a collaboration agreement with Oregon State University. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.93 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -28.4% Sales Growth - Q/Q8.68% P/E-0.79
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-7.88% ROE-11.19% ROI
Current Ratio6.33 Quick Ratio Long Term Debt/Equity Debt Ratio0.21
Gross Margin Operating Margin-11.69% Net Profit Margin-11.95% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities10 K Cash From Operating Activities580 K Gross Profit
Net Profit-1.16 M Operating Profit-1.14 M Total Assets54.14 M Total Current Assets50.78 M
Total Current Liabilities8.02 M Total Debt Total Liabilities16 M Total Revenue8.77 M
Technical Data
High 52 week7.05 Low 52 week1.06 Last close1.36 Last change-2.16%
RSI48.31 Average true range0.11 Beta0.35 Volume52.37 K
Simple moving average 20 days-1.29% Simple moving average 50 days-4.42% Simple moving average 200 days-34.44%
Performance Data
Performance Week-6.85% Performance Month-0.73% Performance Quart-15% Performance Half21.43%
Performance Year-1.45% Performance Year-to-date-79.7% Volatility daily3.6% Volatility weekly8.05%
Volatility monthly16.49% Volatility yearly57.13% Relative Volume97.12% Average Volume40.67 K
New High New Low-1.22%

News

2019-02-21 20:00:00 | Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019

2019-02-15 20:00:00 | Aradigm Announces Plans for Reorganization Under Chapter 11 of the U.S. Bankruptcy Code

2019-01-30 08:00:00 | Aradigm Announces Submission of Responses to EMA Day 120 Questions and Meeting with FDA

2019-01-16 08:00:00 | Aradigm Announces Detailed Third Party Evaluation Results for Apulmiq FDA/Linhaliq EMA

2018-12-20 08:00:00 | Aradigm Announces Results of Third Party Verification for Apulmiq formerly Linhaliq

2018-11-15 08:05:46 | Aradigm: 3Q Earnings Snapshot

2018-11-15 08:00:00 | Aradigm Announces Third Quarter 2018 Financial Results

2018-10-15 08:01:00 | Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team

2018-09-25 08:10:00 | Consolidated Research: 2018 Summary Expectations for Community Health, Aradigm, Avnet, Sanchez Energy, Black Stone Minerals, and Navient — Fundamental Analysis, Key Performance Indications

2018-08-14 08:08:26 | Aradigm: 2Q Earnings Snapshot

2018-08-14 08:00:00 | Aradigm Announces Second Quarter 2018 Financial Results

2018-07-31 07:55:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Community Health, Monotype Imaging, Cardlytics, Sanchez Energy, First Horizon National, and Aradigm — New Research Emphasizes Economic Growth

2018-07-30 07:40:00 | New Research Coverage Highlights ProPetro Holding, Aradigm, Ocean Power Technologies, Icahn Enterprises, Granite Point Mortgage Trust, and PBF Logistics LP — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-07-06 08:00:00 | Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Directors

2018-05-15 08:05:42 | Aradigm: 1Q Earnings Snapshot

2018-05-15 08:00:00 | Aradigm Announces First Quarter 2018 Financial Results

2018-04-16 08:20:00 | New Research Coverage Highlights Aradigm, Ultra Petroleum, TRI Pointe Group, Finisar, Tesla, and The Progressive — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-04-09 07:20:00 | Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis

2018-04-05 08:00:00 | Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission

2018-03-23 08:22:12 | Aradigm reports 4Q loss

2018-03-23 08:00:00 | Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results

2018-03-12 13:35:00 | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm

2018-03-12 11:29:00 | FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aradigm Corporation ARDM & Lead Plaintiff Deadline: March 12, 2018

2018-03-12 11:25:03 | Aradigm Files MAA for Bronchiectasis Candidate in the EU

2018-03-12 11:20:00 | The Klein Law Firm Reminds Shareholders of Aradigm Corporation of a Class Action and a Lead Plaintiff Deadline of March 12, 2018 ARDM

2018-03-12 10:30:00 | Glancy Prongay & Murray LLP Reminds Investors of the March 12, 2018 Deadline in the Class Action Lawsuit Against Aradigm Corporation

2018-03-10 12:46:00 | MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm

2018-03-09 16:01:00 | ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Aradigm Corporation to Contact the Firm

2018-03-09 15:34:00 | March 12th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aradigm Corporation ARDM

2018-03-09 10:51:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aradigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2018 - ARDM

2018-03-09 08:40:00 | DEADLINE REMINDER NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm

2018-03-09 08:00:00 | Aradigm Submits Marketing Authorisation Application MAA to EMA for EU Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis

2018-03-08 17:11:00 | Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Aradigm Corporation Investors ARDM

2018-03-08 13:55:00 | ARDM EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Aradigm Corporation and a Lead Plaintiff Deadline of March 12, 2018

2018-03-08 13:20:00 | MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation

2018-03-07 14:00:00 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aradigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2018 - ARDM

2018-03-07 12:08:00 | 5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation

2018-03-07 10:15:00 | DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aradigm Corporation ARDM & Lead Plaintiff Deadline: March 12, 2018

2018-03-06 18:46:00 | ARDM INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aradigm Corporation Investors

2018-03-06 15:30:00 | ARDM EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Aradigm Corporation and a Lead Plaintiff Deadline of March 12, 2018

2018-03-05 18:42:00 | IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation

2018-03-05 14:15:00 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aradigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2018 – ARDM

2018-03-02 23:25:00 | FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Aradigm Corporation to Contact the Firm

2018-03-02 15:49:00 | The Klein Law Firm Reminds Shareholders of Aradigm Corporation of Commencement of a Class Action and a Lead Plaintiff Deadline of March 12, 2018 ARDM

2018-03-02 11:56:00 | DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation

2018-03-01 14:37:00 | ARDM SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Aradigm Corporation and a Lead Plaintiff Deadline of March 12, 2018

2018-03-01 11:40:00 | MARCH 12 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation

2018-02-28 14:30:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aradigm Corporation of Class Action Lawsuit and Upcoming Deadline - ARDM

2018-02-28 13:45:00 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Aradigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2018 - ARDM

2018-02-27 17:55:00 | ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aradigm Corporation To Contact The Firm